Psoriasis epidemiology: the interplay of genes and the environment.
Enamandram, Monica, and Alexa B Kimball. 2013. “Psoriasis Epidemiology: The Interplay of Genes and the Environment.”. The Journal of Investigative Dermatology 133 (2): 287-9.
Search
Search results
2980 results found
Adverse Reactions to Biologics in Psoriasis.
Lockwood, Stephen J, Lisette M Prens, and Alexa B Kimball. 2018. “Adverse Reactions to Biologics in Psoriasis.”. Current Problems in Dermatology 53: 1-14.
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich, Kristian, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, et al. 2017. “Tildrakizumab versus Placebo or Etanercept for Chronic Plaque Psoriasis (reSURFACE 1 and ReSURFACE 2): Results from Two Randomised Controlled, Phase 3 Trials.”. Lancet (London, England) 390 (10091): 276-88.
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
Kimball, Alexandra B, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Enkeleida Nikaï, Baojin Zhu, et al. 2016. “Impact of Ixekizumab on Psoriasis Itch Severity and Other Psoriasis Symptoms: Results from 3 Phase III Psoriasis Clinical Trials.”. Journal of the American Academy of Dermatology 75 (6): 1156-61.
Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.
Kimball, A B, A N Naegeli, E Edson-Heredia, C-Y Lin, C Gaich, E Nikaï, K Wyrwich, and G Yosipovitch. 2016. “Psychometric Properties of the Itch Numeric Rating Scale in Patients With Moderate-to-Severe Plaque Psoriasis.”. The British Journal of Dermatology 175 (1): 157-62.
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
Kimball, A B, K A Papp, K Reich, M Gooderham, Q Li, N Cichanowitz, C La Rosa, and A Blauvelt. 2020. “Efficacy and Safety of Tildrakizumab for Plaque Psoriasis With Continuous Dosing, Treatment Interruption, Dose Adjustments and Switching from Etanercept: Results from Phase III Studies.”. The British Journal of Dermatology 182 (6): 1359-68.
Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
Papp, K A, K Reich, A Blauvelt, A B Kimball, M Gooderham, S K Tyring, R Sinclair, et al. 2019. “Efficacy of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Trials at Weeks 12 and 28.”. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (6): 1098-1106.
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kimball, A B, M Augustin, K B Gordon, G G Krueger, D Pariser, S Fakharzadeh, K Goyal, et al. 2018. “Correlation of Psoriasis Activity With Socioeconomic Status: Cross-Sectional Analysis of Patients Enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).”. The British Journal of Dermatology 179 (4): 984-86.
A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-term treatment of stasis dermatitis.
Weiss, Stefan C, Josephine Nguyen, Susan Chon, and Alexa B Kimball. 2005. “A Randomized Controlled Clinical Trial Assessing the Effect of Betamethasone Valerate 0.12% Foam on the Short-Term Treatment of Stasis Dermatitis.”. Journal of Drugs in Dermatology : JDD 4 (3): 339-45.
Understanding patient engagement in psoriasis treatment.
Golbari, N M, S J Lockwood, M L Porter, and A B Kimball. 2018. “Understanding Patient Engagement in Psoriasis Treatment.”. The British Journal of Dermatology 178 (4): 988-89.